S U M M A R Y Polycystic ovary syndrome (PCOS) is a common endocrinopathy in women of reproductive age. Although genetic linkage analyses have demonstrated a susceptibility locus for PCOS mapping to the fibrillin-3 gene, the presence of fibrillin proteins in normal and polycystic ovaries has not been characterized. This study compared and contrasted fibrillin-1, -2, and -3 localization in normal and polycystic ovaries. Immunohistochemical stainings of ovaries from 21 controls and 9 patients with PCOS were performed. Fibrillin-1 was ubiquitous in ovarian connective tissue. Fibrillin-2 localized around antral follicles and in areas of folliculolysis. Fibrillin-3 was present in a restricted distribution within the specialized perifollicular stroma of follicles in morphological transition from primordial to primary type [transitional follicles (TFs)]. Fibrillin-1 and -2 stainings of PCOS ovaries were similar to those of the controls. However, in eight of the nine PCOS ovaries, there was a decrease in the number of TFs associated with fibrillin-3, including no staining in five PCOS samples; decreased number of fibrillin-3associated TFs/mm 2 was confirmed by quantitative analysis. Our findings support a role for fibrillin-3 in the pathogenesis of PCOS and suggest fibrillin-3 may function in primordial to primary follicle transition. We propose that loss of fibrillin-3 during folliculogenesis may be an important factor in PCOS pathogenesis. (J Histochem Cytochem 58:903-915, 2010) 
POLYCYSTIC OVARY SYNDROME (PCOS) is a common endocrinopathy affecting an estimated 6-10% of women worldwide (Azziz et al. 2009 ). It represents the most common endocrinopathy of women of reproductive age. Although descriptions of polycystic ovaries date back to the early 1700s, variable degrees of virilization, menstrual abnormalities, and bilaterally enlarged polycystic ovaries form the basis for the definition of PCOS (Stein and Leventhal 1935) . In addition to the clinical manifestations of infertility and virilization, metabolic consequences of PCOS include obesity, type II diabetes, hyperlipidemia, hypertension, and cardiovascular disease (Fleischman and Mansfield 2005) .
To date, there is no overall consensus on the definition of PCOS or the criteria used for diagnosis. Current understanding for diagnosis encompasses the 1990 National Institutes of Health criteria (Zawadski and Dunaif 1992) , Rotterdam 2003 criteria (Rotterdam ESHRE/ ASRM-Sponsored PCOS Consensus Workshop Group 2004 , and most recently the Androgen Excess-PCOS (AE-PCOS) Society criteria (Azziz et al. 2009 ). According to the AE-PCOS Society's working definition, PCOS is a disorder of androgen excess or hyperandrogenism with the following clinical findings: hyperandrogenism (hirsuitism and/or hyperandrogenemia), ovarian dysfunction (oligo-anovulation and/or polycystic ovaries), and the exclusion of other androgen excess-related disorders (Azziz et al. 2009 ).
PCOS has a familial tendency and as such is considered to be a complex trait with a major genetic component (Amato and Simpson 2004) . Numerous candidate genes have been proposed for involvement in PCOS (Urbanek et al. 1999; Amato and Simpson 2004; Unluturk et al. 2007; Dasgupta and Reddy 2008) . In particular, a candidate gene region on chromosome 19p13.2 has been identified (Urbanek et al. 2005) . This PCOS susceptibility locus maps closely to D19S884 by genetic linkage analysis of short-tandem repeat polymorphisms and PCOS family-based association in 367 families (Urbanek et al. 2005) . Genes that map to within 100 kb of D19S884 are FBN3 (encoding fibrillin-3), ELAVL1 (encoding an mRNA-binding protein), and CCL25 (encoding a thymus-expressed chemokine) (Urbanek et al. 2005) . The dinucleotide repeat D19S884, which maps to intron 55 of the FBN3, was identified as the most likely PCOS susceptibility locus, and this polymorphic variant within FBN3 confers an increased risk of PCOS (Urbanek et al. 2005; Stewart et al. 2006; Ewens et al. 2010) . The PCOS susceptibility allele, A8, is also associated with metabolic consequences seen in both the women with PCOS and their brothers (Urbanek et al. 2007 ).
Association of PCOS with FBN3 is controversial. A study using single-nucleotide polymorphisms (SNPs) in the vicinity of FBN3 showed no significant associations of FBN3 with PCOS (Prodoehl et al. 2009 ). However, a more recent SNP analysis reaffirmed the association between a region in FBN3 and PCOS (Ewens et al. 2010 ). The differences between these two most recent studies are as follows: (1) Prodoehl et al.' s study was a casecontrol study, whereas Ewens et al.' s study was family based; (2) the sample size in the study by Ewens et al. was larger; and (3) the definition of PCOS in Ewens et al.' s study was much narrower. Because PCOS is known to be a heterogeneous disorder, family-based studies with a narrow clinical definition of PCOS were required to allow the identification of FBN3 as a likely candidate gene.
Expression studies of ovarian tissues showed that levels of FBN1 mRNA are greater than those of FBN2 mRNA and much greater than those of FBN3 mRNA (Prodoehl et al. 2009 ). These differences in mRNA expression levels do not provide important information about protein levels and locations. It is unknown if and where fibrillin-3 microfibrils are found in normal adult human ovary and whether the quantity or distribution of fibrillin-3 is abnormal in PCOS. This information is required in order to elucidate the role, if any, of fibrillin-3 in ovarian function and PCOS.
Fibrillins are multidomain extracellular matrix glycoproteins that are present in all connective tissues (Sakai et al. 1986; Maslen et al. 1991; Corson et al. 1993 Corson et al. , 2004 Zhang et al. 1995) . The expression and distribution of fibrillin-2 and fibrillin-3 are largely limited to fetal development (Zhang et al. 1995; Corson et al. 2004 ). Fibrillins form the backbone structure of small-diameter "microfibrils" (Sakai et al. 1986 Reinhardt et al. 1996; Charbonneau et al. 2003; Corson et al. 2004 ). In addition to this architectural function, fibrillins per-form regulatory functions by binding and sequestering growth factors Ramirez and Sakai 2010) . Interactions between the large latent transforming growth factor-b (TGF-b) complex and fibrillin microfibrils are mediated through direct binding of latent TGF-b-binding protein (LTBP)-1 and LTBP-4 to fibrillin-1 (Isogai et al. 2003; Ono et al. 2009 ). These interactions have formed the basis for proposed pathogenetic mechanisms leading to activation of TGF-b signaling in the Marfan syndrome, an inherited disorder of connective tissue caused by mutations in fibrillin1 (Neptune et al. 2003 ). In addition, fibrillins interact with the prodomains of bone morphogenetic proteins (BMPs) and growth and differentiation factors (GDFs; Gregory et al. 2005; Sengle et al. 2008) , raising the possibility that abnormalities in fibrillin microfibrils may alter BMP and GDF signaling and TGF-b signaling.
Many members of the TGF-b superfamily are involved in the development and function of the ovary. Cell culture studies and studies in rodents have implicated various BMPs in functions ranging from specification of epiblast to become primordial germ cells to recruitment and selection of primordial follicles to enter folliculogenesis and to the maturation and subsequent atresia of follicles (Shimasaki et al. 1999; Kierszenbaum and Tres 2001; Nilsson and Skinner 2003; Drummond 2005) . Genetic evidence, however, provides the most significant demonstration of the importance of growth factor signaling in ovarian follicle development. In sheep, mutations in BMP-15 and GDF-9 can either stimulate ovulation rate or result in ovarian failure after the earliest stages of follicle development (Galloway et al. 2000; Hanrahan et al. 2004; Bodin et al. 2007) , and in humans, mutations in BMP-15 are associated with hypergonadotropic ovarian failure (DiPasquale et al. 2004) .
The genetic linkage of FBN3 to PCOS is intriguing, particularly because a significant role for fibrillins has recently emerged in the control of growth factor signaling. Whether fibrillins control growth factor signaling in the ovary is unknown. It is also unknown to what extent the functions of the fibrillins are overlapping or specific in the ovary. In order to consider potential roles for fibrillin-3 in PCOS, we first determined the presence and distribution of all three fibrillins in normal adult human ovary. In addition, we determined the distribution of fibrillins in ovaries from patients with a history of PCOS. In this report, we identify a significant difference in the quantity of fibrillin-3-associated follicles within the ovaries of women with a clinical history of PCOS as compared with our control population. Our demonstration of the restricted localization of fibrillin-3 to the perifollicular stroma of a subset of follicles suggests a role for fibrillin-3 in the regulation of TGF-b-related growth factors, particularly BMP-4, BMP-7, GDF-9, and/or TGF-b, in the perifollicular stroma. In this context, abnormalities in the structure or quantity of fibrillin-3 are hypothesized to alter the transition of primordial to primary follicles and subsequently influence the growth and maturation of follicles and competent oocytes. These data and hypothesis are consistent with the identification of a PCOS susceptibility locus in FBN3 (Urbanek et al. 2007; Ewens et al. 2010 ).
Materials and Methods

Tissue Samples
Cases for study were identified by searching the University of Washington Medical Center Surgical Pathology archives in accordance with IRB#05-5943E/A01-03 and #05-9266E/A01-02. Search terms included "polycystic ovary syndrome/disease" and "Stein/Leventhal." All identified cases indicating PCOS or Stein/Leventhal syndrome in the clinical history section of the report or in the body of the pathology report were pulled from the archive for study. Where possible, the clinical history of PCOS was confirmed by accessing the patient's medical record. However, because of the archival nature of the study, the criteria for the diagnosis of PCOS were not standardized. Archived slides and blocks from non-neoplastic ovary samples were selected to serve as normal controls, based on non-neoplastic ovarian parenchyma with no histopathological abnormality. At the time of review of the slides, the nature of the sample (control tissue or tissue from patients with a history of PCOS) was withheld. Two surgical pathologists (CDJ and SDB) read the stained sections. In order to quantitate the staining, the slides were scanned by an Olympus Nanozoomer Digital Pathology (NDP) System (Center Valley, PA), and the NDP virtual slide viewer software (Hamamatsu Photonics; Hamamatsu City, Japan) was utilized to determine ovarian area on each of the slides studied.
Immunohistochemistry
Standard immunohistochemical studies were performed on slides from paraffin-embedded tissues using a modified avidin-biotin (ABC) immunoperoxidase method. Pretreatments consisted of 15-min microwave retrieval in 10 mM citrate buffer for fibrillin-1 monoclonal antibody (MAb15, 1 mg/ml, 1:5000 dilution) and 10-min pronase (Calbiochem; San Diego, CA) digestion and 10-min microwave retrieval in 10 mM citrate buffer for fibrillin-2 (MAb48, 1 mg/ml, 1:200 dilution) and fibrillin-3 (MAb129, 1.49 mg/ml, 1:200 dilution) antibodies. Primary antibodies for fibrillin-1 (Kuo et al. 2007 ), fibrillin-2 , and fibrillin-3 ) were all mouse MAbs that have been previously characterized. After incubation with primary antibody, sections were sequentially incubated with secondary antibody (biotinyl horse-anti-mouse) and ABC (Vectastain Elite, Vector Laboratories; Burlingame, CA). Slides were then developed in a solution of 0.5% hydrogen peroxide as substrate and DAB as chromogen for 7 min for each antibody. Positive control tissue was human fetal ovary and human fetal limb tissues that demonstrated positive staining with the studied antibodies. Negative controls consisted of each patient specimen incubated with normal mouse serum in place of the primary antibody.
Statistical Analyses
Ovarian area and number of follicles/mm 2 were calculated using NDP software (Hamamatsu Photonics). Welch's two-tailed t-test for data sets with unequal variances was used to calculate statistical significance. The average ovarian area of PCOS ovary sections was 508 mm 2 (SD 6 259.7), whereas that of the control set was 567 mm 2 (SD 6 368.8). This was not statistically significant (p50.714). Data were considered statistically significant if p,0.05.
Results
Description of Study Samples
Thirty-one specimens were identified for study, of which nine specimens were from individuals with a clinical history of PCOS. Ages of control samples ranged from 17 to 51 years; for PCOS samples, ages ranged from 17 to 45 years. Non-neoplastic ovaries were reviewed from a variety of patients. Ovaries were resected as parts of staging procedures for neoplasms, endometriosis, or other benign disorders, or prophylactically in patients harboring BRCA gene mutations. Where available, additional clinical histories of PCOS samples included amenorrhea, oligomenorrhea, hirsuitism, and obesity. These and other characteristics of each specimen are recorded in Table 1 .
Histology
Routine hematoxylin and eosin (H&E) staining was performed to evaluate each specimen and to compare control ovaries with PCOS ovaries (Figure 1 ). Descriptive characteristics are summarized individually in Table 1 . In addition, after scanning the ovary sections and utilizing image analysis software, quantitative features of the samples, including area of ovary sections and enumeration of transitional follicles (TFs) in each of the samples, were recorded (Table 2) .
A subset of the control ovaries demonstrated very active folliculogenesis with follicles at several stages of development from primordial/primary (transitional) follicles ( Figure 1A ) to secondary and antral follicles (Figures 1B and 1C) , including large antral follicles ( Figure 1D ) or Graafian follicles ( Figure 1E ). A few of the younger control ovaries mostly had TFs with only rare secondary follicles and occasional large antral follicles or follicular cysts. The term "transitional follicles" was chosen to represent the histological gray zone between primordial and primary follicles and to include the many observed follicles with intermediate features. On average, the control Fibrillins in Polycystic Ovary Syndrome ovaries displayed 0.334 TF/mm 2 , and the average ovarian surface area observed on the control slides was 567 mm 2 (Table 2) . Various stages of corpus luteum were also identified in different ovary sections (data not shown). Prominent large vessel hilar vascularity was most notable in a subset of ovaries, typically those that demonstrated senescent changes (data not shown). Small cortical vessels were readily identified in cortical stroma, and active angiogenesis was appreciated in regions of folliculolysis ( Figure 1F ) and of degeneration of corpora lutea (data not shown). Although many of the control ovaries demonstrated cortical stroma extending nearly subjacent to surface epithelium, subepithelial cortical fibrosis was common in the control set of ovaries. Hyperthecosis was inapparent in the control ovaries (data not shown).
The most consistent finding in the ovaries resected from patients with a history of PCOS was the presence of variable numbers of TFs ( Figure 1H ) and the presence of numerous follicle cysts ( Figure 1G ) with degenerative linings (theca-lined cysts) or cysts with attenuated granulosa layers ( Figures 1H and 1I ). Quantitative analysis showed an average of 0.164 TF/mm 2 in PCOS ovaries. Only rare follicle cysts maintained significantly intact granulosa cell layers of late antral/Graafian follicles (data not shown). In addition, intermediary stages of follicle development were quite rare or absent in PCOS ovaries as were corpus luteum (data not shown). Extensive evidence of folliculolysis with multiple scarred follicles was observed ( Figure 1J ). In addition, luteinization of residual theca was readily identified in association with lytic follicles in a subset of the PCOS ovaries ( Figure 1K ), a finding not apparent in the control set of ovaries. These areas of luteinization were seen in addition to the small clusters of luteinized theca cells ( Figure 1L ) (interpreted as hyperthecosis) in most of the PCOS ovaries. Subcapsular fibrosis was common in the PCOS samples ( Figure 1H ), and in a few samples, more extensive cortical fibrosis was identified (data not shown). One of the ovary samples from a patient with a reported history of PCOS (case number 31) was histologically normal with a range of follicle maturation.
Fibrillins in Control Ovaries
All three fibrillins were identified in the control ovaries after immunohistochemical staining (Figure 2 ). Previous studies have demonstrated that fibrillin-2 and fibrillin-3 are restricted to fetal development (Zhang et al. 1995 ; Charbonneau et al. 2003; Corson et al. 2004) . Therefore, these are the first findings to document the presence of fibrillin-2 and fibrillin-3 in adult tissue.
Fibrillin-1
Strong fibrillar staining with antibodies to fibrillin-1 was found diffusely in the ovarian cortex surrounding individual stromal cells and also in association with cortical vessels (Figures 2A, 2D, and 2G ). Variable degrees of decreased staining or a lack of staining subjacent to the surface epithelium were observed (data not shown). This typically correlated with the thickness of subcortical fibrosis. The concentration of fibrillin-1 fibrils was decreased within the region of the theca externa, and only rare fibrillin-1 fibrils were identified within the theca interna ( Figures 2G and 2J ). Fibrillin-1 was observed in association with a subset of TFs, usually the same follicle sets that were also stained with fibrillin-2 antibody or fibrillin-3 antibody or both (see below and Figure 2A ). Increasingly dense fibrillar fibrillin-1 staining was observed in progressive stages of folliculolysis and typically overshadowed the notable staining for fibrillin-2 ( Figures 2M and 2N) . The orientation of the fibrillin-1 fibrils changed during the process of folliculolysis. During the growing follicle stages, fibrillin-1 was predominantly oriented in a concentric fashion following the contour of the theca externa at the perimeter of the follicle (Figures 2D, 2G, and 2J ). As follicle atresia progressed, fibrillin-1 fibrils assumed a perpendicular orientation to the margin of the pre-existing follicle ( Figure 2M) , and by the end of folliculolysis, fibrillin-1 fibrils filled the previous luminal space of the follicle and were a significant component of the subsequent scar ( Figure 2M) . A similar progression of fibrillin-1 staining was observed in association with corpora lutea undergoing regression (data not shown). Fibrillin-1 staining was ubiquitous in the hilar loose stromal connective tissue and vessels and was often accentuated around the coiled hilar arteries producing a very dense or globular perivascular staining pattern (data not shown).
Fibrillin-2
Staining of control ovaries with antibodies to fibrillin-2 revealed a much more restricted distribution than that observed for fibrillin-1 ( Figures 2B, 2E, 2H, 2K, and 2N ). Fibrillin-2 was found within and around subsets of smaller cortical arteries ( Figure 2N ). Fibrillin-2 was seen as concentric layers of fibrils surrounding the periphery of the theca externa and within the outer aspect of the theca externa (Figures 2E, 2H, and 2K ). Most TFs did not have associated fibrillin-2 staining (data not shown). However, occasionally, slight fibrillin-2 staining was seen in the perifollicular stroma of TF clusters that also demonstrated staining with antibodies to fibrillin-3 and/or fibrillin-1 ( Figure 2B) . Staining for fibrillin-2 typically intensified in midstages of folliculogenesis of secondary or later stage follicles (Figures 2E, 2H, and 2K) . In addition, the orientation of the fibrillin-2 fibrils changed from concentric around the follicle perimeter to perpendicular with subsequent extension of fibrillin-2 fibrils from the periphery to the center of the follicle during folliculolysis ( Figure 2N) ; angiogenesis emerged alongside these changes of fibrillin-2. In the late stages of folliculolysis, fibrillin-1 staining was more abundant than that of fibrillin-2 as the scarring process ensued (Figures 2M  and 2N ). Fibrillin-2 staining of vessels at the periphery of the scar was noted ( Figure 2N ).
Fibrillin-3
Fibrillin-3 was identified in a very restricted distribution within adult human ovary ( Figures 2C, 2F, 2I , 2L, and 2O). Fibrillin-3 was localized in the stroma immediately adjacent to a minor subset of TFs ( Figures 2C and 3K-3N) . Often, only rare or a few TFs in a given ovary section demonstrated this perifollicular staining (Table 2) . On average, 0.0409 TF/mm 2 had adjacent fibrillin-3 staining in the control ovaries ( Figure 4 ) (only 12% of the TFs identified by histology were fibrillin-3 positive). Ovaries with more active folliculogenesis typically had readily identifiable staining for fibrillin-3 (Tables 1 and 2) . On the H&E stains of these latter ovaries, clusters of TF have associated plump or slightly epithelioid stromal cells, thus termed "specialized perifollicular stroma" (Figure 1A) . Fibrillin-3 staining was most dense in such areas of specialized perifollicular stroma ( Figures 2C,  3K, 3L, and 3N) . Staining with fibrillin-2 or accentuation of cortical staining with fibrillin-1 was also noted in a subset of clustered TFs with specialized perifollicular stroma (Figures 2A and 2B) . A few of the TFs that have associated staining for fibrillin-3 do not contain observable oocytes possibly representing barren follicles ( Figures 3K and 3M) . Outside the regions of specialized perifollicular stroma, no staining for fibrillin-3 was identified, except in senescent ovaries where small foci of cortical stroma with the appearance of specialized perifollicular stroma demonstrate staining for fibrillin-3 Equivocal staining was identified in case number 24 (E). Focal detectable staining was identified in case numbers 28 (G, arrow) and 23 (H, arrow), and readily identifiable staining was observed in case number 31 (I, arrows). Staining was observed within perifollicular stroma of control ovaries (K-N, arrows) and focally in the cortical stroma of a senescent ovary (O, arrows). Case number 28 showed staining for fibrillin-3 (G, arrow) but no staining with the negative control, normal mouse serum (NMS; J). Bar 5 50 mm.
( Figure 2O ). No fibrillin-3 staining was identified in association with maturing antral follicles (Figures 2F,  2I , and 2L), folliculolysis ( Figure 2O ), or corpora lutea (data not shown). In addition, there was no staining of cortical or hilar vasculature with antibodies to fibrillin-3 (data not shown).
Fibrillins in PCOS Ovaries
Staining of PCOS ovaries was similar to that of control ovaries for both fibrillin-1 and fibrillin-2. However, staining for fibrillin-3 was decreased in PCOS ovaries compared with control ovaries.
Fibrillin-1 in PCOS
The staining pattern of fibrillin-1 was very similar in the PCOS and control ovaries. Of note, however, was the appearance of fibrillin-1 in areas of cortical fibrosis. In these areas, fibrillin-1 appeared as larger bundles of fibrils between collagen fibers rather than the usual fine reticulated meshwork surrounding individual cortical stromal cells (data not shown).
Fibrillin-2 in PCOS
The distribution of fibrillin-2 staining within PCOS ovaries was very similar to that observed within the control ovaries. However, in the PCOS ovaries, staining for fibrillin-2 was more prominent, probably because of increased folliculolysis in the PCOS ovaries compared with the controls (data not shown).
Fibrillin-3 in PCOS
Fibrillin-3 staining in PCOS ovaries varied between samples. However, fibrillin-3 staining appeared to be mostly decreased or completely absent in the sections examined ( Figures 3A-3H ; Table 2 ). The average number of follicles with associated fibrillin-3 staining in the PCOS samples was 0.0128 TF/mm 2 (Figure 4 ). When identified, fibrillin-3 staining was usually limited to faint perifollicular staining around individual TFs, including some without discernable oocytes, which were included in the counted TFs ( Figures 3G and 3H) . One patient with a clinical history of PCOS (case number 31) had histologically normal ovaries with active folliculogenesis and demonstrated fibrillin-3 staining similar to the control ovaries in both quantity and distribution ( Figure 3I ). Similar to the control ovaries, no fibrillin-3 staining was identified in association with maturing antral/ Graafian follicles, folliculolysis, corpora lutea, or vasculature (data not shown). Quantitation of fibrillin-3 staining in the nine PCOS samples revealed an average of 0.0128 fibrillin-3associated TF/mm 2 . Follicle-associated fibrillin-3 staining in the control set of ovaries (excluding the senescent ovaries, all of which showed stromal foci of fibrillin-3 staining) was 0.0409 fibrillin-3-associated TF/mm 2 . This approximates a significant difference using Welch's two-tailed t-test with a p value of 0.0572. If the one PCOS ovary that was histologically normal (case number 31) is excluded from the analysis, the difference in staining for fibrillin-3 in control and PCOS ovaries is statistically significant with a p value of 0.0009 (Figure 4 ).
Discussion
PCOS is primarily a disorder of androgen excess or hyperandrogenism. In addition to phenotypic virilization and reproductive abnormalities, associated metabolic disturbances including diabetes mellitus and increased cardiovascular risk lead to significant morbidity in these patients (Azziz et al. 2009 ). PCOS is considered to be a multifactorial polygenic disorder. The strongest susceptibility locus associated with PCOS implicates Figure 4 Quantitation of total TF/mm 2 and fibrillin-3-associated TF/mm 2 in control and PCOS ovaries. (A) PCOS ovaries had fewer average TF/mm 2 (0.164 TF/mm 2 ) than control ovaries (0.334 TF/mm 2 ; p50.07). (B) Control ovaries had an average of 0.0409 fibrillin-3-associated TF/mm 2 . The entire set of PCOS ovaries had a decreased average of fibrillin-3associated TF/mm 2 (0.0128 fibrillin-3-associated TF/mm 2 ; p50.057). After exclusion of PCOS case number 31, the average number of fibrillin-3associated TF/mm 2 in PCOS was 0.0027 (p50.0009). Standard deviations and p values are shown. Raw data are shown in Table 2. fibrillin-3 in the pathogenesis of PCOS (Urbanek et al. 2007; Ewens et al. 2010) . Our results support a role for fibrillin-3 in PCOS.
Contradictory conclusions by the two most recent SNP analyses of PCOS (Prodoehl et al. 2009; Ewens et al. 2010 ) may be due to differences in the methodologies used (case-control vs family-based approaches, and the different clinical definitions of PCOS used to select the samples). Although significant differences between PCOS and non-PCOS controls in FBN mRNA expression have not been found (Prodoehl et al. 2009 ), our study of protein localization in ovarian tissue did find differences in fibrillin-3 in our PCOS and non-PCOS samples. Therefore, even with a small randomly selected sample, our study supports a role for fibrillin-3 in PCOS.
Immunolocalization studies in control ovaries demonstrated that the presence of fibrillin-3, in contrast to fibrillin-1 and fibrillin-2, is very limited. Although sparse in quantity, fibrillin-3 consistently localized to the stroma adjacent to a minor subset of primordial or primary follicles (designated here as TFs). It is possible that fibrillin-3 may serve as a biomarker for a specific type of TFs because, of the total 0.334 TF/mm 2 , only 0.0409 TF/mm 2 was associated with fibrillin-3 staining. Because fibrillin-1 and fibrillin-2 were identified around TFs that also displayed fibrillin-3, fibrillin-3 may be expressed before the other fibrillins, marking an earlier subset of follicles than those marked by all three fibrillins. In general, we found the most abundant fibrillin-3 staining in a subset of those ovaries with active folliculogenesis, displaying follicles at various stages of maturation (Table 1; case numbers 1 , 6-8, 10, 11, 18) . Although fibrillin-3 was also identified in the stroma adjacent to only rare or a few isolated TFs within a given ovary, dense fibrillin-3 staining was notable in the stroma associated with clusters of some TFs. On the basis of these observations, we propose that fibrillin-3 forms a specialized stroma around transient TFs as they differentiate from primordial to primary follicles.
In order to test whether fibrillin-3 may contribute to the pathogenesis of PCOS, we quantitated the number of TFs/mm 2 and the number of fibrillin-3-positive TFs/mm 2 in archived samples diagnosed as PCOS compared with control samples. Criteria for diagnosis of PCOS were not standardized, and only nine samples were available. However, using this approach, we were nevertheless able to determine that the number of TFs/mm 2 and the number of fibrillin-3-positive TFs/mm 2 were reduced in the PCOS samples. The reduction in the number of TFs/mm 2 did not reach statistical significance (p50.070). However, the reduction in the number of fibrillin-3-positive TFs/mm 2 approached statistical significance (p50.057). Of the nine PCOS samples, one (case number 31) was histologically normal in appearance and in fibrillin-3 staining. Although this patient had a clinical history of PCOS, the morphological findings within this ovary sample including active folliculogenesis were atypical for a patient with this disorder, which is commonly associated with abnormal folliculogenesis and infertility. If this sample is omitted from the calculations, then the reduction in the number of fibrillin-3-positive TFs/mm 2 was statistically significant (p50.0009). On the basis of these results, we conclude that PCOS is a heterogeneous disorder at the molecular level, and we hypothesize that fibrillin-3 may play a primary role in most cases of PCOS.
The importance of TGF-b superfamily members in the control of folliculogenesis, together with evolving concepts of how the fibrillin microfibril network regulates TGF-b and BMP signaling Ramirez and Sakai 2010) , suggests that fibrillins may perform significant roles in ovarian function, including folliculogenesis. Some members of the TGF-b superfamily interact with fibrillin microfibrils, either directly (Gregory et al. 2005; Sengle et al. 2008) or through an intermediary molecule, LTBP (Isogai et al. 2003; Ono et al. 2009 ). Fibrillins have been shown to be required for specific developmental sequences and cellular functions involving growth factor signaling. FBN2-null mice demonstrated a limb-patterning defect associated with loss of BMP signaling (Arteaga-Solis et al. 2004 ). FBN1deficient mice displayed defects in distal alveolar septation caused by abnormal activation of TGF-b signaling (Neptune et al. 2003) .
Whether fibrillin-3 binds to and regulates BMPs and/or TGF-b is unknown. However, because both fibrillin-1 and fibrillin-2 share the same binding repertoires (Isogai et al. 2003; Sengle et al. 2008) , it seems likely that fibrillin-3 also performs similar molecular functions. However, distinct organ-specific functions appear to be determined by temporal and tissue-specific differences in gene expression rather than by distinct molecular interactions. For example, the early and specific expression of fibrillin-2 in the interdigital space (Charbonneau et al. 2010 ) may explain the defect in limb patterning in FBN2-null mice, whereas the ubiquitous postnatal expression of FBN1, in contrast to FBN2, may explain defects in homeostasis found in FBN1deficient mice. From the restricted localization and apparent transient temporal expression of fibrillin-3 in the TF-specialized perifollicular stroma, we predict that fibrillin-3 may be responsible for the regulation of BMPs and/or TGF-b in these TFs. Evidence exists in rodents that BMP-4 and BMP-7 produced by prethecal stromal cells are involved in the transition of a primordial follicle to a primary follicle and in the subsequent survival of follicles (Lee et al. 2001; Nilsson and Skinner 2003) . The production of these growth factors by prethecal stroma (specialized perifollicular stroma) in conjunction with the demonstrated restricted localization of fibrillin-3 to this specialized stroma suggests an important role for fibrillin-3 in the regulation of growth Fibrillins in Polycystic Ovary Syndrome factors required for the transition of primordial to primary follicles.
Dysregulation of multiple TGF-b-related proteins including BMP-4, BMP-7, anti-Müllerian hormone, activins, inhibins, GDF-9, and BMP-15 has been implicated in the impaired follicular growth that characterizes PCOS (Jonard and Dewailly 2004; Maciel et al. 2004; Pangas and Matzuk 2004; Dumesic et al. 2007a,b) . A balancing act between these growth factors influences androgen production by the follicle and subsequent follicle growth and maturation. Intrafollicular androgen excess is thought to be a primary factor in altered and arrested follicle development leading to the morphology of polycystic ovaries and secondary endocrine abnormalities (Jonard and Dewailly 2004) . A fibrillin-3 microfibrillar scaffold may be required to appropriately balance growth factor signaling and androgen production during folliculogenesis.
The tissue-specific localization of fibrillins in adult ovaries has not been previously investigated. In the early embryo, all three fibrillins are expressed ubiquitously in the connective tissue space. The major differences between fibrillins are accounted for by differences in temporal expression rather than tissue-specific expression. On the basis of these studies (Zhang et al. 1995; Corson et al. 2004 ), immunolocalization of fibrillin-2 and fibrillin-3 was not expected in adult tissues. We report here that fibrillin-2 and fibrillin-3, as well as fibrillin-1, are present in adult ovarian tissues.
We showed that fibrillin-1, the most ubiquitous fibrillin in postnatal connective tissues, is the dominant fibrillin in the adult human ovary. This correlates with recent data that FBN1 mRNA expression levels in human ovary are 50-100 times greater than those of FBN2 and 200-1000 times greater than those of FBN3 (Prodoehl et al. 2009 ). In ovarian parenchyma, we identified fibrillin-1 throughout the cortical stroma, hilar connective tissues, and vessels. Fibrillin-1 accumulates secondarily in regions of neoangiogenesis, vascular regression, and scarring associated with folliculolysis and regression of corpora lutea. It is found only rarely in stroma around TF clusters.
Fibrillin-2 is localized to what may be imagined as activity zones in the ovary. Fibrillin-2 microfibrils are present at the periphery and external layers of the theca externa. They appear to be active participants in the evolution of folliculolysis, often aligning densely in areas of neoangiogenesis. Fibrillin-2 microfibrils are present in a subset of cortical vessels and are occasionally localized to the specialized stroma of TF clusters.
The spatial and temporal expression patterns of BMPs are active throughout folliculogenesis in mammals (Erikson and Shimasaki 2003; Shimasaki et al. 2004) . We demonstrate here that like the BMPs and potentially in concert with BMPs, all three fibrillins are ex-pressed in specific spatial and temporal patterns in adult human ovary.
As such, the fibrillin microfibril network within human ovary is the first example of an adult organ in which there is a dynamic interplay between all three fibrillins. We propose that each of the fibrillins is spatially and temporally located in the same adult organ and that coordination of the specific spatial and temporal expression of fibrillins may be required for normal folliculogenesis. Loss of fibrillin-3 function, because fibrillin-3 is the specific fibrillin associated with the transition from primordial to primary follicle, may be the most disruptive to folliculogenesis. In contrast to recently published results (Prodoehl et al. 2009 ), our data strongly indicate that additional studies aimed at determining the role of fibrillin-3 in the pathogenesis of PCOS merit investigation.
